Grant of new options

Norman Broadbent ties 17% of equity to tough, long-term performance targets.

What the company is saying

Norman Broadbent plc announces the grant of 345,000 share options, representing 17.2% of issued share capital, to executive directors and employees under its Enterprise Management Incentive Share Option Scheme. The company frames the grant as part of an 'ambitious growth plan' and links vesting strictly to performance on Net Fee Income, share price, and EBITDA. The announcement details the allocation by individual, the precise vesting schedule, and the financial thresholds required for each tranche to vest. Language is factual, with no promotional claims or forward-looking statements beyond the description of performance hurdles. The company emphasizes governance and alignment with shareholder interests by tying rewards to measurable outcomes. There is no attempt to present the grant as an immediate catalyst or to overstate its impact.

What the data suggests

The data shows 345,000 options granted at a nominal value of five pence per share, with vesting over three years and strict performance conditions. Up to 50% of options vest only if cumulative Net Fee Income reaches at least £40.6m, with full vesting at £49.6m or above. Up to 30% vest if the average share price hits £2.50, with full vesting at £4.50 or above. The remaining 20% require EBITDA of at least £2.8m, with full vesting at £3.4m or above. After this grant, total options outstanding equal 17.2% of the company's issued share capital. The announcement provides no actual financial or operational results, so progress toward these targets cannot be assessed. All disclosed numbers relate to the structure of the scheme, not to company performance or financial trajectory. Data quality for incentive disclosure is high, but the absence of current financials limits broader analysis.

Analysis

The announcement is a standard disclosure of a share option grant under an incentive scheme, with all key claims supported by specific numerical data. The only forward-looking elements are the performance targets for vesting, which are clearly stated as conditions rather than achievements. There is no promotional or exaggerated language; the tone is factual and proportionate to the content. No large capital outlay is disclosed, and the benefits (option vesting) are contingent on future performance over a three-year period. The announcement does not attempt to frame the grant as an immediate value driver or overstate its impact. There is no gap between narrative and evidence, as all claims are either realised (grant of options) or clearly conditional (vesting criteria).

Risk flags

• ●The performance targets for vesting are ambitious, with Net Fee Income needing to reach at least £40.6m for partial vesting and £49.6m for full vesting, but no current or historical figures are disclosed. This creates uncertainty about whether these hurdles are achievable.
• ●The share price and EBITDA targets are similarly demanding, requiring an average share price of £2.50 to £4.50 and EBITDA of £2.8m to £3.4m, with no baseline provided. Investors cannot assess the probability of vesting without knowing current performance levels.
• ●The grant dilutes existing shareholders by up to 17.2% if all options vest, but the announcement does not discuss the potential impact on capital structure or shareholder returns if targets are met.

Bottom line

This is a standard incentive scheme grant, not an immediate value driver or operational update. The company has set high performance bars for management and staff to earn equity, but provides no information on current results or progress toward these targets. For investors, the announcement signals alignment of management interests with long-term performance, but offers no new insight into underlying business momentum or near-term catalysts. The absence of financial results or operational data means the market cannot judge the likelihood of vesting or the risk of dilution. To change this assessment, the company would need to disclose actual Net Fee Income, EBITDA, and share price trends. The key takeaway is that meaningful dilution is possible, but only if management delivers substantial growth over at least three years.

Announcement summary

(AIM: NBB) Norman Broadbent plc granted options over, in aggregate, 345,000 ordinary shares of £0.05 each to both Executive Directors and certain employees under its Enterprise Management Incentive Share Option Scheme on 14 August 2026. The options are exercisable at nominal value of five pence per Ordinary Share. The options will vest over a three-year period from date of grant and are subject to the achievement of three performance conditions. Up to 50% of the options will vest based on cumulative Net Fee Income performance, up to 30% based on the Company's share price performance, and the remaining 20% based on cumulative underlying EBITDA performance. For the Net Fee Income target, vesting begins at £40.6m and reaches full vesting at £49.6m or above. For the share price target, vesting begins at an average share price of £2.50 and reaches full vesting at £4.50 or above. For the EBITDA target, vesting begins at £2.8m and reaches full vesting at £3.4m or above.

Disagree with this article?